COVID-19 vaccines and decreased transmission of SARS-CoV-2

go back to reference Callaway E (2021) Delta coronavirus variant: scientists brace for impact. Nature 595(7865):17–18. https://doi.org/10.1038/d41586-021-01696-3 (PMID: 34158664)CrossRefPubMed Callaway E (2021) Delta coronavirus variant: scientists brace for impact. Nature 595(7865):17–18. https://​doi.​org/​10.​1038/​d41586-021-01696-3 (PMID: 34158664)CrossRefPubMed

go back to reference Ferrara F, Vitiello A (2021a) Scientific hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 imbalance. Cardiovasc Toxicol. https://doi.org/10.1007/s12012-021-09649-y (Epub ahead of print. PMID: 33835386; PMCID: PMC8032553)CrossRefPubMedPubMedCentral Ferrara F, Vitiello A (2021a) Scientific hypothesis for treatment of COVID-19’s lung lesions by adjusting ACE/ACE2 imbalance. Cardiovasc Toxicol. https://​doi.​org/​10.​1007/​s12012-021-09649-y (Epub ahead of print. PMID: 33835386; PMCID: PMC8032553)CrossRefPubMedPubMedCentral

go back to reference Ferrara F, Vitiello A (2021b) Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedeberg’s Arch Pharmacol. https://doi.org/10.1007/s00210-021-02049-7CrossRef Ferrara F, Vitiello A (2021b) Efficacy of synthetic glucocorticoids in COVID-19 endothelites. Naunyn Schmiedeberg’s Arch Pharmacol. https://​doi.​org/​10.​1007/​s00210-021-02049-7CrossRef

go back to reference Ferrara F, Porta R, D’Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02401-5CrossRefPubMedPubMedCentral Ferrara F, Porta R, D’Aiuto V, Vitiello A (2020) Remdesivir and COVID-19. Ir J Med Sci. https://​doi.​org/​10.​1007/​s11845-020-02401-5CrossRefPubMedPubMedCentral

go back to reference Huff HV, Singh A (2020) Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis 71(10):2752–2756. https://doi.org/10.1093/cid/ciaa654 (PMID: 32463076; PMCID: PMC7314132)CrossRefPubMed Huff HV, Singh A (2020) Asymptomatic transmission during the coronavirus disease 2019 pandemic and implications for public health strategies. Clin Infect Dis 71(10):2752–2756. https://​doi.​org/​10.​1093/​cid/​ciaa654 (PMID: 32463076; PMCID: PMC7314132)CrossRefPubMed

go back to reference Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan ST (2020) COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules 26(1):39. https://doi.org/10.3390/molecules26010039 (PMID: 33374759; PMCID: PMC7795815)CrossRefPubMedCentral Khan M, Adil SF, Alkhathlan HZ, Tahir MN, Saif S, Khan M, Khan ST (2020) COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules 26(1):39. https://​doi.​org/​10.​3390/​molecules2601003​9 (PMID: 33374759; PMCID: PMC7795815)CrossRefPubMedCentral

go back to reference Knoll MD, Wonodi C (2021) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 397(10269):72–74. https://doi.org/10.1016/S0140-6736(20)32623-4 (Epub 2020 Dec 8. PMID: 33306990; PMCID: PMC7832220)CrossRefPubMed Knoll MD, Wonodi C (2021) Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet 397(10269):72–74. https://​doi.​org/​10.​1016/​S0140-6736(20)32623-4 (Epub 2020 Dec 8. PMID: 33306990; PMCID: PMC7832220)CrossRefPubMed

go back to reference Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo AM (2021) SARS-CoV-2 variants and vaccines. N Engl J Med. https://doi.org/10.1056/NEJMsr2105280 Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz-Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao-Restrepo AM (2021) SARS-CoV-2 variants and vaccines. N Engl J Med. https://​doi.​org/​10.​1056/​NEJMsr2105280

go back to reference Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R (2021) Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 27(5):790–792. https://doi.org/10.1038/s41591-021-01316-7 (Epub 2021 Mar 29. PMID: 33782619)CrossRefPubMed Levine-Tiefenbrun M, Yelin I, Katz R, Herzel E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R (2021) Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 27(5):790–792. https://​doi.​org/​10.​1038/​s41591-021-01316-7 (Epub 2021 Mar 29. PMID: 33782619)CrossRefPubMed

go back to reference Lurie N, Saville M, Hatchett R, Halton J (2020) Developing Covid-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973. https://doi.org/10.1056/NEJMp2005630 (Epub 2020 Mar 30 PMID: 32227757)CrossRefPubMed Lurie N, Saville M, Hatchett R, Halton J (2020) Developing Covid-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973. https://​doi.​org/​10.​1056/​NEJMp2005630 (Epub 2020 Mar 30 PMID: 32227757)CrossRefPubMed

go back to reference Petter E, Mor O, Zuckerman N, Oz-Levi D, Younger A, Aran D, Erlich Y (2021) Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv. https://doi.org/10.1101/2021.02.08.21251329CrossRef Petter E, Mor O, Zuckerman N, Oz-Levi D, Younger A, Aran D, Erlich Y (2021) Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. medRxiv. https://​doi.​org/​10.​1101/​2021.​02.​08.​21251329CrossRef

go back to reference Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577 (Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181)CrossRefPubMed Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group (2020) Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N Engl J Med 383(27):2603–2615. https://​doi.​org/​10.​1056/​NEJMoa2034577 (Epub 2020 Dec 10. PMID: 33301246; PMCID: PMC7745181)CrossRefPubMed

go back to reference Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H (2021) Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 384(19):1824–1835. https://doi.org/10.1056/NEJMoa2034201CrossRefPubMed Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, Berghmans PJ, Kimmel M, Van Damme P, de Hoon J, Smith W, Stephenson KE, De Rosa SC, Cohen KW, McElrath MJ, Cormier E, Scheper G, Barouch DH, Hendriks J, Struyf F, Douoguih M, Van Hoof J, Schuitemaker H (2021) Interim results of a phase 1–2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med 384(19):1824–1835. https://​doi.​org/​10.​1056/​NEJMoa2034201CrossRefPubMed

go back to reference Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations December 2020–March 2021. MMWR Morb Mortal Wkly Rep 70(13):495–500. https://doi.org/10.15585/mmwr.mm7013e3 (PMID: 33793460; PMCID: PMC8022879)CrossRefPubMedPubMedCentral Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, Gaglani M (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers—eight U.S. locations December 2020–March 2021. MMWR Morb Mortal Wkly Rep 70(13):495–500. https://​doi.​org/​10.​15585/​mmwr.​mm7013e3 (PMID: 33793460; PMCID: PMC8022879)CrossRefPubMedPubMedCentral

go back to reference Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. https://doi.org/10.1007/s11845-020-02440-yCrossRefPubMedPubMedCentral Vitiello A, Ferrara F (2020) Remdesivir versus ritonavir/lopinavir in COVID-19 patients. Ir J Med Sci. https://​doi.​org/​10.​1007/​s11845-020-02440-yCrossRefPubMedPubMedCentral

go back to reference Vitiello A, Ferrara F (2021a) Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 38(Supplement):S129–S130. https://doi.org/10.4103/lungindia.lungindia_803_20 (PMID: 33687000)CrossRefPubMedPubMedCentral Vitiello A, Ferrara F (2021a) Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19. Lung India 38(Supplement):S129–S130. https://​doi.​org/​10.​4103/​lungindia.​lungindia_​803_​20 (PMID: 33687000)CrossRefPubMedPubMedCentral

go back to reference Vitiello A, Ferrara F (2021b) Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. https://doi.org/10.1007/s00508-021-01855-6 (Epub ahead of print. PMID: 33877436)CrossRefPubMedPubMedCentral Vitiello A, Ferrara F (2021b) Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients. Wien Klin Wochenschr. https://​doi.​org/​10.​1007/​s00508-021-01855-6 (Epub ahead of print. PMID: 33877436)CrossRefPubMedPubMedCentral

go back to reference Vitiello A, Ferrara F (2021c) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https://doi.org/10.1016/j.rmed.2021.106322CrossRefPubMedPubMedCentral Vitiello A, Ferrara F (2021c) Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. https://​doi.​org/​10.​1016/​j.​rmed.​2021.​106322CrossRefPubMedPubMedCentral

go back to reference Vitiello A, Ferrara F, La Porta R (1971) Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. https://doi.org/10.1007/s11845-020-02482-2CrossRef Vitiello A, Ferrara F, La Porta R (1971) Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. https://​doi.​org/​10.​1007/​s11845-020-02482-2CrossRef

go back to reference Vitiello A, Porta R, Pianesi L, Ferrara F (2021a) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https://doi.org/10.1007/s11845-021-02584-5 (Epub ahead of print. PMID: 33710481)CrossRefPubMedPubMedCentral Vitiello A, Porta R, Pianesi L, Ferrara F (2021a) COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view. Ir J Med Sci. https://​doi.​org/​10.​1007/​s11845-021-02584-5 (Epub ahead of print. PMID: 33710481)CrossRefPubMedPubMedCentral

go back to reference Vitiello A, La Porta R, D’Aiuto V, Ferrara F (2021b) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https://doi.org/10.1016/j.humimm.2021.01.007CrossRefPubMedPubMedCentral Vitiello A, La Porta R, D’Aiuto V, Ferrara F (2021b) Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol. https://​doi.​org/​10.​1016/​j.​humimm.​2021.​01.​007CrossRefPubMedPubMedCentral

go back to reference Vitiello A, Pelliccia C, Ferrara F (2021c) Drugs acting on the renin–angiotensin system and SARS-CoV-2. Drug Discov Today. https://doi.org/10.1016/j.drudis.2021.01.010CrossRefPubMedPubMedCentral Vitiello A, Pelliccia C, Ferrara F (2021c) Drugs acting on the renin–angiotensin system and SARS-CoV-2. Drug Discov Today. https://​doi.​org/​10.​1016/​j.​drudis.​2021.​01.​010CrossRefPubMedPubMedCentral

go back to reference Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 (PMID: 33306989; PMCID: PMC7723445)CrossRefPubMedPubMedCentral Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111. https://​doi.​org/​10.​1016/​S0140-6736(20)32661-1 (PMID: 33306989; PMCID: PMC7723445)CrossRefPubMedPubMedCentral

go back to reference Wang R, Chen J, Hozumi Y, Yin C, Wei GW (2020) Decoding asymptomatic COVID-19 infection and transmission. J Phys Chem Lett 11(23):10007–10015. https://doi.org/10.1021/acs.jpclett.0c02765 (PMID: 33179934; PMCID: PMC8150094)CrossRefPubMedPubMedCentral Wang R, Chen J, Hozumi Y, Yin C, Wei GW (2020) Decoding asymptomatic COVID-19 infection and transmission. J Phys Chem Lett 11(23):10007–10015. https://​doi.​org/​10.​1021/​acs.​jpclett.​0c02765 (PMID: 33179934; PMCID: PMC8150094)CrossRefPubMedPubMedCentral

go back to reference Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://doi.org/10.1001/jama.2020.12839 (PMID: 32648899)CrossRefPubMed Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782–793. https://​doi.​org/​10.​1001/​jama.​2020.​12839 (PMID: 32648899)CrossRefPubMed

go back to reference Yu X, Yang R (2020) COVID19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses 14(4):474–475. https://doi.org/10.1111/irv.12743 (Epub 2020 Apr 15. PMID: 32246886; PMCID: PMC7228388)CrossRefPubMedPubMedCentral Yu X, Yang R (2020) COVID19 transmission through asymptomatic carriers is a challenge to containment. Influenza Other Respir Viruses 14(4):474–475. https://​doi.​org/​10.​1111/​irv.​12743 (Epub 2020 Apr 15. PMID: 32246886; PMCID: PMC7228388)CrossRefPubMedPubMedCentral